Essential tuberculosis medicines and health outcomes in countries with a national essential medicines list [PDF]
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2022 Background: Tuberculosis (TB) remains a major cause of morbidity and mortality globally despite effective treatments. Along with high-quality health services, essential medicines are a key tool in curbing TB related mortality.
Darshanand Maraj +2 more
doaj +4 more sources
National Essential Medicines List and policy practice: A case study of China’s health care reform [PDF]
BMC Health Services Research, 2012 Background In 2009, China implemented the national essential medicines system by enacting the National Essential Medicines List 2009. According to the policy of this system, primary health care institutions can only stock and use essential medicines on ...
Tian Xin, Song Yaran, Zhang Xinping
doaj +4 more sources
Medicines not recommended for inclusion in the who essential medicines list: a retrospective observational study [PDF]
Frontiers in MedicineBackgroundThe WHO Model List of Essential Medicines (EML) includes those medicines that offer the best health payback for individuals and health systems. It serves as a guide for countries to develop and update national EMLs.
Enrico Costa +10 more
doaj +5 more sources
Revising the WHO Essential Medicines List for paediatric rheumatology [PDF]
Pediatric Rheumatology Online Journal, 2021 Christiaan Scott +6 more
doaj +6 more sources
The Consistency Between the Chinese Essential Medicines List and Treatment Guidelines—Taking Oncology Medicines as an Example [PDF]
Frontiers in Public Health, 2022 The concepts of “essential medicine” and “national medicine policy” were first put forward for the first time at the World Health Assembly in 1975 in an effort to alleviate the problem of medicine unavailability in developing and poor countries.
Luyan Cheng +9 more
doaj +2 more sources
NOACs Added to WHO’s Essential Medicines List: Recommendations for Future Policy Actions [PDF]
Global Heart, 2020 The introduction of non-vitamin K antagonists oral anticoagulants, a class of medicines which includes dabigatran, apixaban, edoxaban and rivaroxaban, has resulted in improvements in the safety and efficacy of non valvular atrial fibrillation treatment ...
Mariachiara Di Cesare +8 more
doaj +2 more sources
A quantitative comparison of essential cardiovascular medicines from countries in the Southern African Development Community to the WHO model essential medicines list [PDF]
Journal of Pharmaceutical Policy and Practice, 2022 Background Globally, cardiovascular disease (CVD) is a leading cause of death and disproportionately affects low- and middle-income countries (LMICs).
Ian Naicker +2 more
doaj +2 more sources
Evaluation of alignment of the reimbursement medicines list for children in Albania with the WHO essential medicines list for children [PDF]
Journal of Pharmaceutical Policy and PracticeBackground: The WHO Essential Medicine List for Children was released on the 30th anniversary of the general Essential Medicine List in 2007, to recognise special needs for medicines in children, and to promote the inclusion of paediatric medicines in ...
E. Petro +4 more
doaj +2 more sources
Estimation of cost-based prices for injectable medicines in the WHO Essential Medicines List [PDF]
BMJ Open, 2019 Objectives Challenges remain in ensuring universal access to affordable essential medicines. We previously estimated the expected generic prices based on cost of production for medicines in solid oral formulations (ie, capsules or tablets) on the WHO ...
Dzintars Gotham +2 more
doaj +2 more sources
Revising the WHO Essential Medicines List for paediatric rheumatology update [PDF]
Pediatric Rheumatology Online Journal, 2022 Waheba Slamang +4 more
doaj +2 more sources